{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:27:12Z","timestamp":1768292832132,"version":"3.49.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.soc.2020.08.001","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T10:31:12Z","timestamp":1603189872000},"page":"39-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Surgical Management of Neuroendocrine Tumor Liver Metastases"],"prefix":"10.1016","volume":"30","author":[{"given":"Catherine G.","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott K.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrikha","family":"Chandrasekharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.soc.2020.08.001_bib1","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihim\u00e4ki","year":"2016","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.soc.2020.08.001_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.soc.2020.08.001_bib3","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2020.08.001_bib4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A\u00a05-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.hoc.2015.08.006","article-title":"Clinical Presentation and Diagnosis of Neuroendocrine Tumors","volume":"30","author":"Vinik","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib6","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.soc.2020.08.001_bib7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.suc.2019.04.014","article-title":"Evaluation and Management of Neuroendocrine Tumors of the Pancreas","volume":"99","author":"Scott","year":"2019","journal-title":"Surg Clin North Am"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.6004\/jnccn.2018.0056","article-title":"NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018","volume":"16","author":"Shah","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.beem.2016.01.002","article-title":"Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms","volume":"30","author":"Modlin","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.soc.2020.08.001_bib10","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1245\/s10434-014-3728-0","article-title":"Pancreastatin predicts survival in neuroendocrine tumors","volume":"21","author":"Sherman","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2020.08.001_bib11","article-title":"It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors","author":"Tran","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","article-title":"Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging","volume":"23","author":"Dromain","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2214\/ajr.180.1.1800121","article-title":"MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques","volume":"180","author":"Dromain","year":"2003","journal-title":"AJR Am J Roentgenol"},{"issue":"11","key":"10.1016\/j.soc.2020.08.001_bib14","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.2967\/jnumed.111.101675","article-title":"The role of 68Ga-DOTATATE PET\/CT in suspected neuroendocrine tumors","volume":"53","author":"Haug","year":"2012","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2214\/ajr.182.3.1820559","article-title":"Carcinoid Tumors of the Small Bowel: A Multitechnique Imaging Approach","volume":"182","author":"Horton","year":"2004","journal-title":"Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/PAS.0b013e3181ce1447","article-title":"Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set","volume":"34","author":"Klimstra","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.soc.2020.08.001_bib17","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10585-014-9681-2","article-title":"Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors","volume":"31","author":"Sherman","year":"2014","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib18","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.surg.2014.08.008","article-title":"A\u00a0practical method to determine the site of unknown primary in metastatic neuroendocrine tumors","volume":"156","author":"Maxwell","year":"2014","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J\u00a0Am Coll Surg"},{"issue":"5","key":"10.1016\/j.soc.2020.08.001_bib20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/01.sla.0000161981.58631.ab","article-title":"Neuroendocrine hepatic metastases: does aggressive management improve survival?","volume":"241","author":"Touzios","year":"2005","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.soc.2020.08.001_bib21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"The oncologist"},{"issue":"12","key":"10.1016\/j.soc.2020.08.001_bib22","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.soc.2020.08.001_bib23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1067\/msy.2003.114","article-title":"Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study","volume":"133","author":"Elias","year":"2003","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"32","key":"10.1016\/j.soc.2020.08.001_bib25","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study","volume":"34","author":"Yao","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2020.08.001_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/SLA.0b013e3181bdf8cf","article-title":"Hepatic Metastases From Neuroendocrine Tumors With a \u201cThin Slice\u201d Pathological Examination: They are Many More Than You Think","volume":"251","author":"Elias","year":"2010","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1477-2574.2010.00198.x","article-title":"Long-term survival after surgical management of neuroendocrine hepatic metastases","volume":"12","author":"Glazer","year":"2010","journal-title":"HPB (Oxford)"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib28","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.surg.2014.08.009","article-title":"Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients","volume":"156","author":"Graff-Baker","year":"2014","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib30","first-page":"1091","article-title":"Cytoreductive hepatic surgery for neuroendocrine tumors","volume":"108","author":"McEntee","year":"1990","journal-title":"Surgery"},{"key":"10.1016\/j.soc.2020.08.001_bib31","first-page":"1","article-title":"Solid liver tumors","volume":"22","author":"Foster","year":"1977","journal-title":"Major Probl Clin Surg"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0011-3840(81)80009-3","article-title":"Liver metastases","volume":"18","author":"Foster","year":"1981","journal-title":"Curr Probl Surg"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9610(99)80107-X","article-title":"Hepatic resection for metastatic neuroendocrine carcinomas","volume":"169","author":"Que","year":"1995","journal-title":"Am J Surg"},{"issue":"4","key":"10.1016\/j.soc.2020.08.001_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.surg.2008.06.008","article-title":"The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors","volume":"144","author":"Chambers","year":"2008","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","article-title":"Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?","volume":"159","author":"Maxwell","year":"2016","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.surg.2018.04.070","article-title":"Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs)","volume":"165","author":"Scott","year":"2019","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib37","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.surg.2017.05.030","article-title":"Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors","volume":"163","author":"Morgan","year":"2018","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","article-title":"The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"issue":"11","key":"10.1016\/j.soc.2020.08.001_bib39","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/bjs.8842","article-title":"Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases","volume":"99","author":"Capurso","year":"2012","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.soc.2020.08.001_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jamaoncol.2017.3326","article-title":"Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival","volume":"4","author":"Daskalakis","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11605-009-1115-0","article-title":"Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients","volume":"14","author":"Franko","year":"2010","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.soc.2020.08.001_bib42","article-title":"Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms","author":"Kaemmerer","year":"2019","journal-title":"Ann Surg"},{"issue":"24","key":"10.1016\/j.soc.2020.08.001_bib43","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.soc.2020.08.001_bib44","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1245\/s10434-018-6490-x","article-title":"Peritoneal Metastases in Colorectal Cancer","volume":"25","author":"Jacobson","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib45","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1245\/s10434-020-08316-w","article-title":"The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms","volume":"27","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.soc.2020.08.001_bib46","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/cncr.32870","article-title":"The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma","volume":"126","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.surg.2013.05.030","article-title":"Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases)","volume":"155","author":"Elias","year":"2014","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib48","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1245\/s10434-020-08321-z","article-title":"The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors","volume":"27","author":"Chicago Consensus Working Group","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2020.08.001_bib49","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/SLA.0b013e31828ee17c","article-title":"Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study","volume":"257","author":"Le Treut","year":"2013","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.surg.2017.05.006","article-title":"Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review","volume":"162","author":"Moris","year":"2017","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.soc.2020.08.001_bib51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib52","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/bja\/87.3.447","article-title":"Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours","volume":"87","author":"Kinney","year":"2001","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.1964.03860070072004","article-title":"The Carcinoid Crisis","volume":"114","author":"Kahil","year":"1964","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib54","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.surg.2018.04.093","article-title":"A\u00a0prospective study of the pathophysiology of carcinoid crisis","volume":"165","author":"Condron","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.soc.2020.08.001_bib55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jclinane.2016.03.008","article-title":"Development of effective prophylaxis against intraoperative carcinoid crisis","volume":"32","author":"Woltering","year":"2016","journal-title":"J\u00a0Clin Anesth"},{"issue":"8","key":"10.1016\/j.soc.2020.08.001_bib56","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jso.23323","article-title":"Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients","volume":"107","author":"Massimino","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.soc.2020.08.001_bib57","doi-asserted-by":"crossref","unstructured":"Tran CG, Sherman SK, Howe JR. Small bowel neuroendocrine tumors. Curr Probl Surg, in press. 2020:100823. https:\/\/doi.org\/10.1016\/j.cpsurg.2020.100823","DOI":"10.1016\/j.cpsurg.2020.100823"},{"issue":"2","key":"10.1016\/j.soc.2020.08.001_bib58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.soc.2010.11.002","article-title":"Radiofrequency ablation of neuroendocrine hepatic metastasis","volume":"20","author":"Gamblin","year":"2011","journal-title":"Surg Oncol Clin N Am"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jso.20237","article-title":"Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases","volume":"90","author":"Elias","year":"2005","journal-title":"J\u00a0Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2020.08.001_bib60","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/hep.23181","article-title":"Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis","volume":"50","author":"N'Kontchou","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib61","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.surg.2010.09.014","article-title":"Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up","volume":"148","author":"Akyildiz","year":"2010","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib62","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejrad.2008.08.008","article-title":"Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation","volume":"72","author":"Vogl","year":"2009","journal-title":"Eur J Radiol"},{"issue":"13","key":"10.1016\/j.soc.2020.08.001_bib63","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1245\/s10434-011-1832-y","article-title":"Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis","volume":"18","author":"Mayo","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.soc.2020.08.001_bib64","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jvir.2007.04.018","article-title":"Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver","volume":"18","author":"Ruutiainen","year":"2007","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"28","key":"10.1016\/j.soc.2020.08.001_bib65","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib66","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib67","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10022","key":"10.1016\/j.soc.2020.08.001_bib68","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.soc.2020.08.001_bib69","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.soc.2020.08.001_bib70","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.soc.2013.06.012","article-title":"Translational research in endocrine surgery","volume":"22","author":"Sherman","year":"2013","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"10.1016\/j.soc.2020.08.001_bib71","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib72","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000473892","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy","volume":"105","author":"Garcia-Carbonero","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.soc.2020.08.001_bib73","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib74","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.soc.2020.08.001_bib75","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.soc.2020.08.001_bib76","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1530\/ERC-16-0147","article-title":"Analysis of potential response predictors to capecitabine\/temozolomide in metastatic pancreatic neuroendocrine tumors","volume":"23","author":"Cives","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.soc.2020.08.001_bib77","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.soc.2020.08.001_bib78","doi-asserted-by":"crossref","first-page":"TPS4145","DOI":"10.1200\/jco.2015.33.15_suppl.tps4145","article-title":"A\u00a0randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211)","volume":"33","author":"Kunz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2020.08.001_bib79","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000498887","article-title":"Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses","volume":"108","author":"de Mestier","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib80","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1245\/s10434-014-3981-2","article-title":"Impact of (68)Ga-DOTATATE PET\/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum","volume":"22","author":"Ilhan","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib81","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jso.25812","article-title":"Impact of initial imaging with gallium-68 dotatate PET\/CT on diagnosis and management of patients with neuroendocrine tumors","volume":"121","author":"Crown","year":"2020","journal-title":"Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2020.08.001_bib82","first-page":"403","article-title":"Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis","volume":"8","author":"Ka\u00e7maz","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.soc.2020.08.001_bib83","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320720300697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320720300697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:05:47Z","timestamp":1760961947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320720300697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1055320720300697"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2020.08.001","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical Management of Neuroendocrine Tumor Liver Metastases","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2020.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}